GlobeNewswire Inc | Oct 21, 2020 04:05PM EDT

October 21, 2020

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced todayitwill be presenting new scientific research at the American College of Rheumatologys (ACR) first virtual annual meeting, ACR Convergence 2020. The event is being held online from November 5-9, 2020.

Exagens Chief Scientific Officer, Anja Kammesheidt, shared, Exagen is honored to have had the opportunity to partner with such great collaborators on this years abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus. We are pleased to be sharing these data at this years virtual ACR event.

Below is the list of accepted abstracts along with links to each:

Saturday, November 7th

Poster Presentation | Presented by Michelle Petri, MD | Abstract #0857Title Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial LaboratorySessionTitle SLE Treatment Poster ISession Time: 9:00 am 11:00 am EST

Sunday, November 8th

Oral Presentation | Presented by YevgeniyaGartshteyn, MD | Abstract #1510Title Platelet-bound C4d is Associated with Platelet Activation and Arterial Thrombotic EventsSessionTitle SLE Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (15071511)Session Time: 3:00 pm 3:50 pm EST

Oral Presentation | Presented by Michelle Petri, MD | Abstract #1513Title Role of Platelet C4d in Thrombosis and Lupus NephritisSessionTitle SLE Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (15121516)Session Time: 4:00 pm 4:50 pm EST

Monday, November 9th

Poster Presentation | Presented by YevgeniyaGartshteyn, MD | Abstract #1792Title Platelet-bound C4d is Associated with an Increased Risk of Arterial and Venous Thromboses in SLESessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster III: Bench to BedsideSession Time: 9:00 am 11:00 am EST

Poster Presentation | Presented by Rosalind Ramsey-Goldman, MD | Abstract #1797Title A Multianalyte Assay Panel (MAP) With Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA And Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 YearsSessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster III: Bench to BedsideSession Time: 9:00 am 11:00 am EST

Poster Presentation | Presented by Jill Buyon, MD | Abstract #1808Title Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)SessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster III: Bench to BedsideSession Time: 9:00 am 11:00 am EST

* Abstracts will remain live until March 11, 2021

AboutExagen Inc.

Exagenis dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.Exagenhas developed and is commercializing a portfolio of innovative testing products under its AVISE brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagens goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagens model of integrating testing products and therapeutics positionsExagento offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visitwww.Exagen.com

Forward Looking Statements

Exagencautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the companys current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE test. The inclusion of forward-looking statements should not be regarded as a representation byExagenthat any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagens business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, Exagens commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; third party payers not providing coverage and adequate reimbursement for the companys testing products or promoted therapeutics; the companys ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the companys business; risks associated with maintaining third-party partnerships and Exagens performance thereunder; and other risks described in the companys prior press releases and the Companys filings with theSecurities and Exchange Commission(SEC), including under the heading Risk Factors in the companys Annual Report on Form 10-K and any subsequent filings with theSEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, andExagenundertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

InvestorsWestwicke PartnersMike CavanaughMike.Cavanaugh@westwicke.com646.677.1838

CompanyExagen Inc.Kamal Adawi, Chief Financial Officerkadawi@exagen.com760.477.5514